Chief Physician of Medical Oncology for Melanoma and Sarcoma, MD. He has long been engaged in the pharmacological treatment of malignant melanoma, sarcoma, renal cell carcinoma and urothelial carcinoma, with a primary focus on clinical new‑drug research and translational research for melanoma. He obtained his Doctor of Medicine degree in Oncology from Peking University in 2011, and visited the Melanoma Institute Australia (MIA) and Westmead Hospital in Sydney for further study in 2012. As a key contributor to clinical trials, he has facilitated the approval of multiple new drugs for marketing, and several innovative treatment regimens have been incorporated into domestic and international clinical practice guidelines. Among his major recent studies, the findings of CAP 03‑NEO, a three‑drug combination neoadjuvant therapy for acral melanoma, have gained international recognition, and the relevant results were presented as an oral report at the 2025 ASCO Annual Meeting. He is the chief editor of the Chinese Society of Clinical Oncology Melanoma Patient Education Handbook, promotes standardized cancer diagnosis and treatment, and delivers precision‑medicine services to patients.